Treatment of older patients with mantle-cell lymphoma

New England Journal of Medicine

Volumn 367, Issue 6, 2012, Pages 520-531

  Kluin Nelemans, Hanneke C ^a   Hoster, E ^d   Hermine, O ^m   Walewski, J ^w   Trneny, M ^x   Geisler, C H ^z   Stilgenbauer, S ^e   Thieblemont, C ⁿ   Vehling Kaiser, U ^f   Doorduijn, J K ^b   Coiffier, B ^o   Forstpointner, R ^d   Tilly, H ^p   Kanz, L ^g   Feugier, P ^q   Szymczyk, M ^w   Hallek, M ^h   Kremers, S ⁱ   Lepeu, G ^r   Sanhes, L ^s   Zijlstra, J M ^c   Bouabdallah, R ^t   Lugtenburg, P J ^b   Macro, M ^u   Pfreundschuh, M ^j   Prochazka V ^y   Di Raimondo, F ^aa   Ribrag, V ^v   Uppenkamp, M ^k   Andre M ^ab   Klapper, W ^l   Hiddemann, W ^d   Unterhalt, M ^d   Dreyling, M H ^d   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f Tagesklinik Hämatologie Onkologie   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ CARITAS KRANKENHAUS   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

^k Klinikum der Stadt   (Germany)

^l UNIVERSITY OF KIEL   (Germany)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

^o CENTRE HOSPITALIER LYON SUD   (France)

^p CENTRE HENRI BECQUEREL   (France)

^q Service d'Hematologie Biologique   (France)

^r CENTRE HOSPITALIER D AVIGNON   (France)

^s Centre Hospital Marechal Joffre   (France)

^t Hôpital Ste Marguerite   (France)

^u Service d'Hematologie   (France)

^v INSTITUT GUSTAVE ROUSSY   (France)

^w INSTITUTE OF ONCOLOGY   (Poland)

^x CHARLES UNIVERSITY   (Czech Republic)

^y PALACKÝ UNIVERSITY   (Czech Republic)

^z Rigshospitalet   (Italy)

^aa Ospedale Ferratotto   (Italy)

^ab UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84864715966     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1200920     Document Type: Article

References (26)

1. Swerdlow SH, Campo E, Seto M, Muller-Hermelink H-K. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008:229-32.
2. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009;2009:542-51. [Erratum, Hematology Am Soc Hematol Educ Program 2011;2011:562.]
3. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-94. (Pubitemid 34177435)
4. Hiddemann W, Dreyling M, Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003;30:Suppl 2:16-20. (Pubitemid 36342268)
5. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546-53. (Pubitemid 29075241)
6. Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000;18:773-9. (Pubitemid 30106607)
7. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71. (Pubitemid 39517009)
8. Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001;42:1015-22. (Pubitemid 32827523)
9. Unterhalt M, Hermann R, Koch P, et al. Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 1996;88:453a. abstract.
10. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8. (Pubitemid 44920177)
11. Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma - consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009;2:103-11.
12. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-53. [Erratum, J Clin Oncol 2000;18:2531.] (Pubitemid 29162950)
14. Whitehead JR. The design and analysis of sequential clinical trials. 2nd ed., rev. Chichester, United Kingdom: Wiley, 1997.
15. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008;111:558-65. [Erratum, Blood 2008;111:5761.]
16. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-9. (Pubitemid 47069536)
17. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:171-8.
18. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-92. (Pubitemid 46211378)
19. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progressionfree survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 2005;105:2677-84. (Pubitemid 40450320)
20. Geisler CH. Front-line treatment of mantle cell lymphoma. Haematologica 2010;95:1241-3.
21. Harel S, Delarue R, Ribrag V, Dreyling M, Hermine O. Treatment of younger patients with mantle cell lymphoma. Semin Hematol 2011;48:194-207.
22. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma 2009;50:716-22.
23. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphoma: final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). In: Program and abstracts of the American Society of Hematology 52nd Annual Meeting, Orlando, FL, December 4-10, 2010:114. abstract.
24. Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26-38.
25. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequencedependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007;21:524-8.
26. Kluin-Nelemans HC, Doorduijn JK. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 2011;48:208-13.